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Abstract
Although the Papanicolaou smear has been successful in decreasing cervical cancer incidence in 
the developed world, there exist many challenges for implementation in the developing world. 
Quantitative cytology, a semi-automated method that quantifies cellular image features, is a 
promising screening test candidate. The nested structure of its data (measurements of multiple 
cells within a patient) provides challenges to the usual classification problem. Here we perform a 
comparative study of three main approaches for problems with this general data structure: a) 
extract patient-level features from the cell-level data; b) use a statistical model that accounts for 
the hierarchical data structure; and c) classify at the cellular level and use an ad hoc approach to 
classify at the patient level. We apply these methods to a dataset of 1,728 patients, with an average 
of 2,600 cells collected per patient and 133 features measured per cell, predicting whether a 
patient had a positive biopsy result. The best approach we found was to classify at the cellular 
level and count the number of cells that had a posterior probability greater than a threshold value, 
with estimated 61% sensitivity and 89% specificity on independent data. Recent statistical 
learning developments allowed us to achieve high accuracy.
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1. INTRODUCTION
The problem treated here may be described as classification of a population given data from 
a random sample of members and hence could be considered a classification problem using 
hierarchical data. In our context, the “population” is a patient, and we have measurements on 
a sample of cells from the patient. More specifically, we want to predict if a patient has 
cervical neoplasia (cancer or pre-cancer) given quantitative measurements on cells collected 
by a cervical brushing similar to a Papanicolaou (Pap) smear. Other examples of these types 
of problems are classifying measurements of cell nuclei from fine needle aspirates to 
diagnose breast cancer [1], measurements of brushing of cells or mouthwashes for patient 
diagnosis of oral cancer and periodontal pathogens [2–4], and flow cytometric 
measurements [5].
We present here a review of new and existing methods for this type of problem and an 
empirical comparative study of these methods as applied to our specific example. There are 
three general categories of methods considered. The first one involves producing patient 
level features from the cell level data, e.g. by summary statistics. For example, one could 
compute moments of the cell level variables and plug those patient level features into a 
classification algorithm. The second general approach is to develop a statistical model for 
the cell level data, and using Bayes theorem or some other method to produce a patient level 
prediction such as a posterior probability of disease. The third category involves 
classification at the cell level, and then using some method to predict at the patient level; for 
example, predict that the patient has disease if the number of cells classified as precancerous 
is above a threshold. Note that this approach requires cell level ground truth in order to learn 
the classifier at the cell level. In our data, we do have cell classes obtained by laborious 
examination of numerous individual cells. These three general categories are not meant to be 
mutually exclusive and exhaustive – some methods may rightly be considered to belong to 
more than one of the categories, and new methods may be developed which don’t belong to 
any.
In the case study presented here, we report on the application of 21 methods from these three 
categories, including some novel statistical approaches. We use a dataset of 1,728 patients 
with an average of 2,600 cells per patient (range 30–6,258). The cell level data are produced 
by a high-resolution automated image cytometer, which consists of an image processing 
system connected to a microscope. The system produces 104 cell level features for each 
individual cell that is measured. The objective is to produce a patient level diagnosis that 
would be used in cervical cancer screening, as the Pap smear is used now for this purpose.
This manuscript is organized as follows. In Section 2.1, we present more details on our 
application, including some biological motivation for giving special consideration for some 
of the cell level features. In Section 2.2–2.8, we present the algorithms used in the 
comparative study, organized according to the three categories introduced above. Section 3 
presents the results of our comparative study with an emphasis on finding the most accurate 
predictor for our specific problem. The discussion section is a summary of our findings to 
the specific application, and presents some more general discussion of this class of 
problems.
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2. METHODS
2.1 Overview of study procedures
Our specific objective was to develop an automated algorithm for the diagnosis of high-
grade pre-cancer (cervical intraepithelial neoplasia [CIN]) or cancer. Thus, we identified a 
patient as “positive for high-grade CIN” if her cervical tissue had a histological grade of 
high-grade lesion or worse, including a histology reading of CIN 2, CIN 3, carcinoma in 
situ, or invasive cancer. A patient was classified as "negative for high-grade CIN” if her 
cervical tissue had a histological grade that indicated low-grade disease or normal (CIN 1, 
human papilloma virus [HPV]-related changes, inflammation, atypia, or normal). The study 
design has been described in the literature [6–8]. Briefly, the patients entered the study in 
one of two possible categories: patients that never had an abnormal Pap smear (screening 
patients), and patients who had a history of an abnormal Pap smear (diagnostic patients). 
High-grade CIN was much more prevalent in the diagnostic than in the screening patients 
(29% versus 2%).
There were 1,850 total patients in our study, of which 1,728 are included in our analysis. 
Patients were excluded if the corresponding cytology diagnosis or histology diagnosis was 
not available. The consensus diagnosis of the patient's histology was regarded as our referent 
standard. A patient's histology was defined to be the worst histologic grade assigned to any 
of her biopsy samples [9]. We sought to predict the dichotomized histologic grade 
(histological grade of high-grade CIN or worse versus low-grade CIN or normal) using 
information obtained from quantitative cytology.
Details of the quantitative cytology procedures are described in [6,10]. Briefly, the 
Cytosavant system first acquired images of Feulgen-Thionin stained cells on a slide [11,12]. 
The cell nucleus images were then segmented and separated to create an individual image 
for each nucleus [13]. A mask was then created for each nucleus image in order to extract 
133 features for each cell [14], generally motivated by known biological changes that take 
place in the cell in its progression toward cancer. The image processing is only meant to be 
applied to images of separate single cells. Based on training data sets from previous studies, 
decision trees were used to sort cell objects into three groups: normal, abnormal, and clumps 
of cells or debris, which were then confirmed by a cytotechnologist [15]. Only images of 
individual cells were used in our analyses. Some algorithms used pre-selected variables 
while others used all 104 features as candidate variables.
2.2 Development of an algorithm for cell classification using quantitative cytology
In the process of selecting the best classifier, a problem may result from the selection of a 
classifier that is over-trained, that is, it works well on the data set that it was trained on but 
poorly on an independent data set. A popular solution is to use cross-validation to obtain 
unbiased estimates of the classifier's performance. We divided the data into three sets: 
training, validation, and test sets [16]. We chose to randomly sample proportions of 40%, 
30%, and 30% for these three data sets, respectively, stratified by the histologic grade. The 
training set was used to estimate the parameters of a classifier, either by using the whole 
training set to fit models with no “free” parameters (e.g., logistic regression) or by using 5-
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fold cross-validation within the training set to choose the model parameters (e.g., the 
penalization parameter of L1-regularized logistic regression). The validation set was used to 
obtain estimates of the trained classifier's performance using the parameters estimated from 
the training set and to select a classifier to apply to the test set. The test set was used to 
obtain an unbiased estimate of the chosen classifier's performance, re-estimating the 
classifier’s parameters (since the chosen algorithm had “free” parameters) using 5-fold 
cross-validation within the combined training and validation sets [16].
We compared all of the methods to the sensitivity and specificity of the Pap smear in the 
following way. The Pap smear is estimated to have 55% sensitivity and 90% specificity 
from our validation set (we use the validation data results since we compared the 
classification methods on this data set). This is consistent with estimates by [6]. The Pap 
smear sensitivity and specificity varies considerably by setting, with reported sensitivities as 
low as 20% and as high as 77% [17,18]. Our comparison was based on a population of 
cancer center providers and thus we expect the comparison to be even more favorable than 
in a developing country and low-resource settings.
To compare the algorithms, we used receiver operating characteristic (ROC) curve analysis. 
The main comparison to the Pap smear was performed by computing the sensitivity 
corresponding to a 90% specificity and comparing the sensitivities among the algorithms. 
Confidence intervals for proportions were estimated using the normal approximation to the 
binomial distribution. The area under the ROC curve (AUC), a commonly used summary 
statistic, summarizes the information over areas of the ROC curve that are clinically 
unimportant, such as areas with low specificity. A screening test with low specificity for a 
low-prevalence disease would potentially lead to many unnecessary treatments. To focus on 
areas of clinical relevance, we calculated the area under a part of the ROC curve. The partial 
AUC (pAUC) is defined to be the area within the curve between a defined interval of either 
sensitivity or specificity, discussed in [19]. We identified the area of interest to be between 
80% and 100% specificity and used the pAUC to further compare the methods. We averaged 
the pAUC over the interval by dividing by the length of the interval (thus, the averaged 
pAUC is equal to pAUC/0.2) and estimated the confidence intervals using bootstrap 
samples. The averaged pAUC is 1.0 for a perfect test and 0.1 for an uninformative test.
2.3 Feature extraction
A simple and intuitive way of dealing with multilevel data is to summarize the data at the 
macro level. For example, we may find the means and variances for the cell-level features 
for each patient and then use those as features to classify at the macro level. Standard 
classification procedures can be applied to the patient-level feature vector since both the 
features and the patient biopsy results are at the same level. Summary features may not 
capture potentially important information about the macro-unit distribution. In our example, 
the DNA Index is usually bimodal so some potentially important information will be lost if 
one simply computes the mean and variance. The bimodality features can be captured using 
a normal mixture model with two modes. Thus, the success of this approach can depend 
critically on which macro-level features are computed.
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To obtain the patient-level features for this class of problem, we (1) calculated summary 
statistics per patient on the cellular variables, and (2) fit normal mixture models to the cell 
distribution within a patient, using the parameters of the model as patient-level features [20]. 
Summary statistics included the mean, standard deviation, skewness, and kurtosis of each 
variable. Most of the cells within a patient, regardless of the patient’s disease status, are 
normal cells. There are also some cells that are undergoing cell division at any given time.
The variable DNA Index, which provides an approximate measure of the amount of nuclear 
DNA in the cells, is one of the most widely used features in quantitative cytology research. 
The DNA Index may indicate whether the cell is normal (DNA Index is approximately 1), 
cycling (DNA Index is approximately 2), or potentially abnormal. For the DNA Index, we 
summarized the distribution using model-based clustering (Mclust function in R) to fit a 
mixture of Gaussian distributions to each patient with two Gaussian components [20]. One 
component was fit around DNA Index 1 to represent the normal cells in the sample (with 
two sets of chromosomes) and another component around DNA Index 2 to represent the 
cycling or potentially abnormal tetraploid cells (with four sets of chromosomes). The five 
patient-level features are thus the mean, standard deviation, and weight of the first 
component and the mean and standard deviation of the second component. In situations 
where the distribution of the variable has more than two modes or is very skewed, more 
complicated techniques can be used.
We applied a variety of classification algorithms to the patient-level features, including 
classification and regression trees (CART), random forests (with 4,000 trees), support vector 
machines (SVM), K-nearest-neighbors, logistic regression, L1-regularized logistic 
regression, elastic-net regularized logistic regression, linear discriminant analysis, lasso, 
ridge regression [16], and regularized linear discriminant analysis using a lasso penalty [21]. 
For regularization methods, the data were scaled to have mean zero and variance one on the 
training set so that the L1 and L2 penalty terms were not dominated by features with large 
relative variance. The training set mean and variance parameters were used to scale the 
validation and test sets.
2.4 Statistical model
We applied novel statistical models that were developed to account for the nested structure 
of the data. The cumulative log-odds (CLO) method assumes that given the disease state, the 
cellular measurements share an identical distribution and are independent of each other, 
modeled by the posterior log-odds of disease [22]. An extension of this method relaxes the 
assumption, allowing for heterogeneity of the distributions of the data within a disease state 
[23]. These methods are briefly described here.
The CLO method assumes that, conditional on the class, the cell feature vectors from the 
same patient are independent and identically distributed (i.i.d.). Let Y ∈ {0,1} be the binary 
indicator of the true class of the patient, respectively representing negative and positive for 
high-grade CIN. Let Si = {xi1, xi2, …, xini} be the unordered ni-tuplet feature vectors 
measured on the ni cells from patient i, where ni is assumed to be noninformative. The x can 
be univariate or multivariate features measured on each cell. Si is a vector of variable 
dimension of the patients’ cell-level measurements. Note that the cells are a sample from the 
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large population of cervical cells in a patient. Let π1 = P(Y = 1) denote the prior probability 
(prevalence) of class 1 at the patient level and let f (Si|Y = 1) denote the conditional 
distribution of the feature vector given the class (Y = 1). Let π(Si) = {π1 f (Si|Y = 1)}/{π1 f 
(Si|Y = 1) + (1 − π1) f (Si|Y = 1) denote the posterior probability of class 1 at the patient level 
given the cellular features. Thus, the posterior log-odds of class 1 is 
 where the f (xij|Y) are 
determined using kernel density estimates. This is referred to as the CLO 1 method. This can 
be rewritten in terms of the cell-level probabilities: 
. Here, Pr(Y = 1|
xij) are the cell-level probabilities and Pr(Y = 1) is the cell-level prior probability of class 1, 
or the probability that a cell comes from a patient in class 1. We refer to this reformulation 
as the CLO 2 method.
The extension of the CLO 1 method assumes the existence of an unobserved latent variable 
U, and that the features are i.i.d. given the class and the latent variable (Yamal et al., 2011). 
Thus, the log-odds of having the disease given the feature vector is
The latent classes are estimated using K-means clustering [16] of the patient-specific kernel 
density estimates along a fixed grid. The clustering is used to find the patients that have 
similar DNA Index distributions; hence, where the CLO method assumption is more likely 
to hold. Given the estimated latent classes, f (x|u, Y) is estimated for each latent class u and 
disease state Y using the kernel density estimate of the pooled cells for all patients in that 
cluster. More details are given in [23].
2.5 Micro-level classification
Our third approach was to perform cell-level classification, and then use the cell-level 
posterior probabilities in order to conduct classification at the patient level. This method was 
motivated by clinical pathologists’ search for abnormal cells – if an abnormal cell is found, 
the pathologist will diagnose the patient as having a disease. A similar simple automated 
method is the ploidy method of counting the number of cells within a patient that have a 
DNA Index value greater than 2.5 (hence, are probably abnormal) and using that to conduct 
the patient classification [6]. The more general class of approaches is to perform the micro-
level classification based on more features than DNA Index and various classification 
methodologies, and then use that information to conduct macro-level classification. For 
example, one can compute the percentage of the cells that were classified as abnormal and 
then create a threshold for the patient to be classified as “abnormal” or not. It is important to 
note that the outcome at the micro level does not have to be the same outcome as the macro-
level outcome.
In order to conduct classification at the cellular level, it is necessary to obtain a “ground 
truth” at the cellular level. We first estimated the cell posterior probability by using the 
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cell’s classification of whether it was an abnormal cell or a negative (including benign and 
cycling) cell. This classification of cells into abnormal or negative groups was done in the 
following way. Cells were classified as being negative if their DNA Index was lower than 
1.2 to reduce the time that cytotechnologists and cytopathologists reviewed the slides and 
because most of these cells are likely negative. Cells with a DNA Index between 1.2 and 1.5 
were systematically reviewed by an experienced cytotechnologist to classify them into either 
the abnormal or negative group although none were classified as abnormal. Similarly, cells 
with a DNA Index higher than 1.5 were reviewed by an experienced cytopathologist to 
confirm truly abnormal cells.
To train classification algorithms for micro-level classification, we used a subset of the data 
with cells with a DNA Index value greater than 1.5; although all cells were used in the 
predictions. This served the purpose of reducing our data set to something more 
computationally manageable as well as not focusing on the cells that could be automatically 
classified as being negative anyway at the cellular level. However, these cells may have 
discriminatory information at the patient level, especially among features other than DNA 
Index, so we included them in the predictions. There were 53,163 negative cells and 4,004 
abnormal cells in this subset of our training data. The estimation of the cell posterior 
probability was done using random forests (with 4,000 trees), K-nearest-neighbors, elastic-
net regularized logistic regression, CART, linear discriminant analysis, regularized 
discriminant analysis, logistic regression (with and without stepwise variable selection), and 
L1-regularized logistic regression. Once we had an estimate of the posterior probability of a 
cell being abnormal, we derived a patient-level feature using the count of cells with a 
posterior probability above varying thresholds.
We present more details on the L1-regularized logistic regression, elastic-net regularized 
logistic regression, and CART because these were the most accurate algorithms.
2.6 L1-regularized logistic regression
In logistic regression, the logit transformation of the conditional mean of y given x is 
modeled using a linear equation: . The model is usually fit 
using maximum likelihood. L1-regularized logistic regression puts a penalty on the sum of 
the absolute values of the coefficients: 
 [24]. The λ parameter 
was estimated using 5-fold cross-validation on the training set.
2.7 The elastic net
The elastic net classifier is a regularization method that performs both regression and 
variable selection [25]. In contrast to L1-regularized logistic regression which has a penalty 
term for the sum of the first norm, the elastic-net regularized logistic regression’s penalty 
term is a weighted sum of the first and second norms: , where 
0 ≤ α ≤ 1 is chosen via cross-validation, and |·|1 and |·|2 denote the first and second norms, 
respectively. The advantage of the elastic net is that it can shrink coefficients down to 0 as 
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(1 − α) increases, effectively performing variable selection, while still encouraging a 
grouping of correlated variables to have either zero or nonzero coefficients.
The parameters of the elastic net were chosen by searching on a grid of the parameters (11 
equally spaced points between 0 and 1 for α; λ ∈ {0, 0.01, 0.1, 1, 10, 100}) and choosing the 
parameters that had the largest sensitivity for 90% specificity using 5-fold cross-validation 
of the training data.
2.8 CART
Classification trees partition the feature space into a set of rectangles where we model the 
response as a constant cm in each region  for m = 1, …, M 
regions [26]. The space is first split into two regions where the mean of y is estimated in 
each of the regions. The split is found by looking at all possible splits on all variables and 
finding the split based on the Gini index. Each region Rm with Nm observations is 
represented by a node m in the tree. The proportion of class k observations in node m is 
given by p̂mk = 1/(Nm) ∑xi∈Rm I{yi = k}, for k = 0, 1. Observations are classified in node m to 
class maxk p̂mk, the majority class of the observations in the training data.
2.9 Software
Statistical analysis was performed using the statistical package R version 2.13.1 (R 
Foundation for Statistical Computing, Vienna, Austria).
3. RESULTS
Histologic grade and the study population (screening or diagnostic) were evenly distributed 
among the training, validation, and test sets (Table 1). A summary of the accuracies of the 
trained algorithms on the validation set is shown in Table 2. We see that many of the 
methods are at least as accurate as clinical cytology. Several algorithms had similar 
sensitivity and pAUC and were highly correlated with each other (Spearman’s rank 
correlation coefficients range 0.58–0.99, p<0.001 for all pairwise comparisons of the 
algorithm prediction scores). The top performers are the classifiers that performed the 
micro-level classification first, and then counted the number of cells that had a posterior 
probability over a threshold. The L1-regularized logistic regression, elastic-net regularized 
logistic regression, and CART cell-level classifiers had the highest sensitivity (66%, 65%, 
and 65% sensitivity, respectively, for 90% specificity) and the same pAUC (0.61) on the 
validation set. Logistic regression and the ploidy method also worked well. Of the patient 
summary-features approaches, the approach that had the best sensitivity and pAUC was 
deriving features via modeling the DNA Index densities within a patient as a mixture of 
normal distributions and using logistic regression.
We then used the validation set results to find an unbiased estimate of the sensitivity and 
specificity on our test set by using the threshold selected from the validation set. The top 
three classifiers were L1-regularized logistic regression, elastic-net regularized logistic 
regression, and CART. The results on the test set are presented in Table 3.
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When applying the L1-regularized logistic regression, elastic net algorithm, and CART to 
the test set to obtain an unbiased estimate of its sensitivity, specificity, and pAUC, we 
combined the training and validation sets and used 5-fold cross-validation to choose the free 
parameters. The optimal λ parameter for L1-regularized logistic regression was λ = 1000 
and the patient score was calculated by counting if there was more than one cell that had a 
prediction greater than 0.12. The optimal parameters for the elastic net were α = 0.5 and λ = 
0.1, leaving only four variables with non-zero coefficient estimates: DNA Index coefficient 
= 0.68, Fractal 1 area = 0.10, Fractal 2 area = 0.05, and Average run percent = 0.04. Variable 
details are provided in [14]. The coefficient estimates are shown in Figure 1. If a patient had 
more than one cell that had a predicted value greater than 0.1, the patient was predicted to 
have high-grade CIN with 61% sensitivity and 89% specificity on the cross-validated 
combined training and validation data.
We therefore used this same threshold (at least three cells) on the test set. The result was 
64% sensitivity (95% CI 54%–74%) and 87% specificity (95% CI 84%–90%) with pAUC 
0.50 (95% CI 0.41–0.60). The positive predictive value was 51% (95% CI 42%–60%) and 
the negative predictive value was 93% (95% CI 90%–95%). The ROC curves for the 
algorithm applied to the validation and test sets are shown in Figure 2.
The L1-regularized logistic regression model was used to predict the cell class (as opposed 
to the patient class) in the test data set. Table 4 gives the cell-level classification confusion 
matrix where 97% of the cells were correctly classified (87% cell-level sensitivity and 98% 
cell-level specificity).
Using the model that was trained on the combined training and validation data, the L1-
regularized logistic regression coefficients are given in Table 5. Based on the magnitude of 
the coefficients (the data were standardized), the top three predictive variables were the 
DNA Index, area (the area of the nucleus), and low DNA area (the fraction of the total 
nuclear area that is occupied by low chromatin).
The screening sample did not contain many patients who were found to have disease, so 
were unable to obtain good estimates of the sensitivity and positive predictive value in that 
population. The specificity in the test screening sample was 96% (95% CI 93%–98%) and 
the negative predictive value was 97% (95% CI 95%–99%).
4. DISCUSSION
From a statistical standpoint, we have done a comparative study of various methods for 
classification of data with a hierarchical, nested structure. We found good sensitivity and 
pAUC in the three general approaches: extracting macro-level features from micro-level 
data, the use of statistical models that account for the hierarchical structure of the data, and 
the micro-level classification and counting the number of abnormal cells. The third approach 
generally had the best accuracy measures when applied to our data but it is not likely to 
dominate the other approaches for all applications. It is common practice to apply many 
methods to a classification problem in the search for an algorithm with high predictive 
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accuracy. The presentation of these general approaches provides a framework for the 
building of a classifier for data with this structure.
We have taken advantage of recent developments in statistical learning for handling high-
dimensional data with many features. In some cases, regularization methods were used to 
perform variable selection, resulting in a more interpretable and parsimonious model. We 
selected our best performing classifier from among a suite of classfiers from the three basic 
methodologies that have been used for this type of hierarchical classification. Other 
promising areas of research in this setting would be to apply ensemble learning methods 
[27] rather than selecting a single classifier and to use the image itself to conduct 
classification [28].
The best performing algorithm we found uses the micro-level classification (with elastic net 
regularized logistic regression) to infer the macro-level class, which mimics the process by 
which clinicians classify Pap smears, i.e., cytopathologists looking for the abnormal cells on 
a slide. This general approach was not very sensitive to the choice of the micro-level 
classifier based on the similarity of the pAUCs and sensitivities in Table 2 and based on 
>99% agreement of the positive cases in the test set between the top three classifiers in 
Table 3. Other approaches, including statistical modeling, also had good performance and 
have promise to improve as new methodologies are developed.
Our best performing algorithm had 61% sensitivity and 89% specificity on the test set – 
which is approximately the same accuracy as the clinically read Pap smear in our data, and 
significantly better than reports on the sensitivity and specificity of the Pap smear in some 
developing countries [29]. Further, the algorithm will give exactly the same score when 
applied to the same data, whereas pathologists have high intra-observer and inter-observer 
variability in grading a slide [18,30,31].
Other research groups have developed algorithms for quantitative cytology using only 
ploidy, i.e., the DNA Index. One such study gave estimates of 54% sensitivity and 97% 
specificity, based on a diagnostic population of patients who were followed by colposcopic 
examination [10]. Others have used ploidy subjectively for classification and did not obtain 
a specific classification algorithm [32–34]. In contrast, we had biopsy results from both 
screening and diagnostic populations and considered over 100 quantitative cytology features 
rather than just DNA Index. Because many of the methods we investigated had similar 
accuracy measures, our results suggest that quantitative cytology is quite robust to the 
specific classification algorithm chosen.
There are three major strengths of this study. First, this is the first comparative study of 
methods for classification of hierarchical data that we are aware of. Second, we took great 
care to obtain unbiased estimates of the performance of the algorithm by using cross-
validation techniques. Finally, our algorithm brings improved performance over other 
quantitative cytology algorithms at no extra cost since it would be employed in the software 
side of the device. A weakness of the study is the mixed population of screening and 
diagnostic patients. Training and testing classification algorithms require sufficient numbers 
of cases and controls. Although quantitative cytology is intended as a screening test, the 
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prevalence of disease is very low in the screening population and training and testing using a 
screening sample was not practical. Hence, we enriched our sample with more patients 
likely to have the disease by using a combination of screening and diagnostic populations. A 
large multi-center trial using screening patients is needed to test any such algorithm. We 
estimate that it would require 15,000 patients assuming 90% power to detect an increase in 
the true positive and true negative rates from 50% and 50% to 60% and 90%, respectively 
[35]. Another possible limitation is some patients had very few cells collected and therefore 
the utility of such an algorithm in these patients is not clear. However, when stratifying the 
test set into subsets of patients with <500 cells and in ranges of 500 (e.g., 500–1000, 1000–
1500, …, >3500), there was no clear degradation in performance, based on the ROC curves, 
between the groups. Additionally, more robust estimation of the classifier performance 
could be obtained by repeating the splitting into training, validation, and test sets.
There are new HPV vaccines, but they do not confer protection against all types of HPV that 
cause cervical cancer [36]. About 30% of cervical cancers will not be prevented by these 
vaccines, thus necessitating the continuation of regular screening programs. Furthermore, 
the uptake of the vaccine has been low, with only 12.5% of eligible women completing the 
3-dose HPV vaccine [37]. With increased use of the HPV vaccine, the prevalence of cervical 
cancer will decrease, resulting in a decreased predictive value of existing screening methods. 
Thus, if costs and accuracy remain the same, the cost-effectiveness of the currently used 
screening tests will only decrease. The results of this study show that quantitative cytology 
provides an alternative with nearly the same accuracy, and, we believe, much lower cost.
Cervical cancer is a preventable disease if it is caught early, especially in the pre-cancerious 
stage. Thus the key to fighting cervical cancer is screening that is accurate and of low cost. 
With advances such as the new HPV vaccine and screening process improvements such as 
those presented in this manuscript, the incidence rates of cervical cancer can be decreased. 
Further, the expansion of cervical cancer screening to developing nations requires 
methodologies that are practical in that setting, which is not the case for the current standard 
of care based on reading of Pap smears by cytopathologists. Quantitative cytology has the 
potential for high impact in low-resource settings due to its minimal training requirements 
and being semi-automated which could increase the speed of analysis and potentialy reduce 
cost [11] and improve patient adherence.
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Figure 1. 
Elastic net coefficient estimates as a function of log(λ) from the combined training/
validation set. The optimal λ, a parameter that specifies the amount of shrinkage of the 
coefficients, was found to be 0.1, and α was found to be 0.5, leaving 4 variables with 
nonzero coefficients. The top horizontal axis indicates the number of non-zero coefficients 
for each choice of λ.
Yamal et al. Page 14
Stat Anal Data Min. Author manuscript; available in PMC 2016 April 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 2. 
Receiver operating characteristic (ROC) curve of the elastic net algorithm applied to the 
validation and test sets.
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Table 2
Summary of estimated sensitivities and the partial AUC for detecting high-grade CIN or worse versus low-
grade CIN or better on the validation set.
Approach
Method Sensitivity (95% 
CI)
for 90% 
specificity
Partial AUC for 
range (80%
–100% specificity) 
(95% CI) Candidate features
Pathologist Clinical Cytology 55% (44%–66%) 0.47 (0.38–0.56) -
CART 42% (32%–52%) 0.37 (0.29–0.46) All 104 quant cytology
Random Forests 53% (42%–64%) 0.48 (0.38–0.58) All 104 quant cytology
Logistic Regression 26% (17%–35%) 0.23 (0.16–0.31) All 104 quant cytology
Patient summary features Elastic Nets 56% (45%–66%) 0.53 (0.43–0.63) All 104 quant cytology
Lasso 59% (49%–69%) 0.54 (0.44–0.64) All 104 quant cytology
Ridge Regression 55% (44%–64%) 0.53 (0.43–0.63) All 104 quant cytology
SVM 52% (41%–63%) 0.51 (0.41–0.61) All 104 quant cytology
k-Nearest Neighbors 38% (28%–48%) 0.38 (0.20–0.37) All 104 quant cytology
Mclust (DNA Index) 60% (50%–70%) 0.54 (0.45–0.63) DNA Index
CLO Method 1 48% (37%–59%) 0.42 (0.33–0.51) DNA Index
Model-based CLO Method 2 55% (44%–66%) 0.47 (0.38–0.58) All 104 quant cytology
Latent Class CLO 47% (36%–58%) 0.40 (0.31–0.50) DNA Index
Cell classification then 
patient classification
Ploidy Method 64% (54%–74%) 0.60 (0.51–0.69) DNA Index
Random Forests 53% (42%–64%) 0.59 (0.50–0.69) All 104 quant cytology
Elastic Net 65% (55%–75%) 0.61 (0.51–0.70) All 104 quant cytology
K-nn 52% (41%–63%) 0.47 (0.37–0.56) All 104 quant cytology
Logistic Regression w variable 
selection 63% (53%–73%) 0.60 (0.51–0.70) All 104 quant cytology
L1-Regularized Logistic Regression 66% (56%–76%) 0.61 (0.52–0.71) All 104 quant cytology
CART 65% (55%–75%) 0.61 (0.52–0.71) All 104 quant cytology
LDA 59% (49%–69%) 0.58 (0.48–0.67) Top 6 RF variables
Regularized LDA 62% (52%–72%) 0.59 (0.49–0.69) All 104 quant cytology
CIN = cervical intraepithelial neoplasia; AUC = area under the receiver operating characteristic curve
Stat Anal Data Min. Author manuscript; available in PMC 2016 April 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Yamal et al. Page 18
Table 3
Summary of estimated sensitivities, specificities, and partial area under the ROC curve on the test set.
Method Sensitivity (95% CI) Specificity (95% CI) Partial AUC for range (0.8–1
specificity) (95% CI)
Regularized Logistic Regression 60% (49%–70%) 89% (86%–92%) 0.49 (0.40–0.59)
Elastic Net 61% (53%–73%) 89% (84%–91%) 0.50 (0.40–0.60)
CART 58% (48%–69%) 90% (87%–92%) 0.49 (0.39–0.58)
ROC = receiver operating characteristic; CART = classification and regression tree
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Table 4
Cell-level posterior probability confusion matrix using L1-regularized logistic regression illustrating the 
classification of each individual cell in the test set.
True Group
Negative Abnormal
Predicted Group Negative 40,378 373
Abnormal 746 2,607
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Table 5
Elastic Net coefficient estimates.
Variable Coefficient
DNA Index 0.68
fractal 1 area 0.10
fractal 2 area 0.05
average run percent 0.04
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